Thymogen (Oglufanide)
ExperimentalThymic dipeptide / researchExperimental
Glu-Trp dipeptide (thymogen) used as an immunomodulator in some CIS markets. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 148698-17-5
- Molecular Weight (MW)
- 333.34 g/mol
- Half-life
- Not firmly established (small dipeptide)
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Immune cells (proposed)
Overview
Glu-Trp dipeptide (thymogen) used as an immunomodulator in some CIS markets. Not FDA-approved.
Protocol
- Dosage Range
- Per study/label outside U.S.; not FDA-approved
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Short thymic dipeptide reported to modulate T-cell and innate responses in regional literature.
Targets
Immune cells (proposed)
Studies
- Thymogen Glu-Trp literature— Journal/year not available
Benefits
Immune-research dipeptide
Potential Side Effects
- Not well characterized in FDA-standard trials
References
- PMID 11726309External link · Year —